COMPANY

Lumos Pharma

Profile checked Oct 10, 2026

Keywords: Growth Hormone Deficiency Obesity & Overweight Progressive Pediatric Brain Cancer LUM-201 NLG802 (indoximod Prodrug)

Timeline

Feb 15, 2027 Trial start Phase 2: Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults source ↗
2027-02 Trial start 3: Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency source ↗
Oct 8, 2026 Trial start Phase 1: Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer source ↗
May 20, 2026 Trial start 3: Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency source ↗
Aug 1, 2023 Trial start Phase 2: A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) source ↗
Feb 18, 2022 Trial start 2: Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213) source ↗
Jul 14, 2021 Trial start Phase 2: PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) source ↗
Dec 31, 2020 Trial start 2: Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial) source ↗

2027-12 (ESTIMATED) · 3 · Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency · NCT06948214
Feb 15, 2028 (ESTIMATED) · Phase 2 · Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults · NCT07754045
2028-03 (ESTIMATED) · Phase 2 · A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211) · NCT05796440
2030-02 (ESTIMATED) · 3 · Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency · NCT07129759
2030-04 (ESTIMATED) · Phase 2 · PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212) · NCT04806854
Oct 8, 2030 (ESTIMATED) · Phase 1 · Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer · NCT07732413

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT06948214	Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency	3	Recruiting	May 20, 2026	2027-12 (estimated)
NCT07754045	Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults	Phase 2	Not yet recruiting	Feb 15, 2027	Feb 15, 2028 (estimated)
NCT07732413	Trial of NLG802 Indoximod Prodrug Plus Temozolomide for Patients With Progressive Pediatric Brain Cancer	Phase 1	Not yet recruiting	Oct 8, 2026	Oct 8, 2030 (estimated)
NCT07129759	Phase 3 Long Term Safety Extension Study of LUM-201 in Children With Growth Hormone Deficiency	3	Not yet recruiting	2027-02	2030-02 (estimated)
NCT04614337	Phase 2 Study of LUM-201 in Children With Growth Hormone Deficiency (OraGrowtH210 Trial)	2	Completed	Dec 31, 2020	Sep 4, 2024 (actual)
NCT05250063	Phase 2 Study of LUM-201 in Children Who Have Previously Completed the LUM-201-01 Trial (OraGrowtH213)	2	Completed	Feb 18, 2022	Jan 22, 2025 (actual)
NCT05796440	A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)	Phase 2	Enrolling by invitation	Aug 1, 2023	2028-03 (estimated)
NCT04806854	PK and PD Study of LUM-201 in Children With Idiopathic Growth Hormone Deficiency: (OraGrowtH212)	Phase 2	Active, not recruiting	Jul 14, 2021	2030-04 (estimated)